This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

PharmaLeaders: Generic Manufacturers Benchmark Report - Financial Benchmarking & Competitive Analysis Of The Leading Generic Players In 2013

List of Figures

Figure 1: Generics Manufacturing Landscape Assessment – FY2012 Corporate Revenue Growth vs. Operating Margin 20Figure 2: Generics Manufacturing Landscape Assessment – FY2012 Generics Sales Growth vs. Operating Margin 21Figure 3: FY2011 and FY2012 Leading Generic Pharmaceutical Companies by Revenue 27Figure 4: FY2012 Leading Generic Pharmaceutical Companies by YTY Revenue Growth 31Figure 5: FY 2011 and FY2012 Leading Generic Pharmaceutical Companies by Operating Income ($m) 35Figure 6: FY2012 Leading Generic Pharmaceutical Companies by YTY Operating Income Growth 38Figure 7: FY 2011 and FY2012 Leading Generic Pharmaceutical Companies by Operating Margin 42Figure 8: Top 30 Generic Pharmaceutical Landscape Assessment – FY2012 SG&A Expense vs. Operating Expense as a Percentage of Revenue 44Figure 9: FY 2011 and FY2012 Leading Generic Pharmaceutical Companies by SG&A Spending ($m) 45Figure 10: FY 2011 and FY2012 Leading Generic Pharmaceutical Companies by SG&A Spending as a Percentage of Revenue 50Figure 11: FY2012 Leading Generic Pharmaceutical Companies by SG&A Spending as a Percentage of Revenue, YTY Change 53Figure 12: FY2011 and FY2012 Leading Generic Pharmaceutical Companies by Operating Expense as a Percentage of Revenue 57Figure 13: FY2011 and FY2012 Leading Generic Pharmaceutical Companies by Debt-to-Assets Ratio 65Figure 14: FY 2011 and FY2012, Leading Generic Pharmaceutical Companies by Cash Ratio 68Figure 15: FY 2011 and FY2012 Leading Generic Pharmaceutical Companies by ROI 71Figure 16: Sun Pharmaceuticals: SWOT Analysis 73Figure 17: Sandoz: SWOT Analysis 76Figure 18: Pharmstandard: SWOT Analysis 79Figure 19: Teva Pharmaceuticals: SWOT Analysis 82Figure 20: Teva Generics Sales in US vs. Rest-of-World (ROW)1, 2009–2012 85Figure 21: Actavis: SWOT Analysis 87Figure 22: Mylan: SWOT Analysis 90Figure 23: Ranbaxy: SWOT Analysis 93Figure 24: Dr. Reddy's: SWOT Analysis 94Figure 25: Covidien: SWOT Analysis 95Figure 26: Hospira: SWOT Analysis 96

Companies Mentioned

Sun Pharmaceuticals: The Benchmark LeaderSandoz PharmstandardTeva PharmaceuticalsActavis Mylan Ranbaxy Dr. Reddy's Covidien Hospira

To order this report: Generic_Drug Industry: PharmaLeaders: Generic Manufacturers Benchmark Report - Financial Benchmarking & Competitive Analysis of the Leading Generic Players in 2013

__________________________Contact Clare: clare@reportlinker.com US:(339) 368 6001 Intl:+1 339 368 6001

SOURCE Reportlinker

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,040.37 +29.69 0.16%
S&P 500 2,111.73 +4.34 0.21%
NASDAQ 5,082.9290 +12.9030 0.25%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs